X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (22) 22
index medicus (21) 21
oncology (16) 16
cancer (15) 15
gej (13) 13
adenocarcinoma (12) 12
aged (12) 12
chemotherapy (12) 12
esophageal neoplasms - pathology (12) 12
female (12) 12
male (12) 12
middle aged (12) 12
adenocarcinoma - pathology (10) 10
gastroesophageal junction (10) 10
adult (9) 9
esophagogastric junction - pathology (9) 9
gastric cancer (9) 9
gastroenterology & hepatology (9) 9
aged, 80 and over (8) 8
barrett's esophagus (8) 8
prognosis (8) 8
surgery (8) 8
carcinoma (7) 7
esophageal cancer (7) 7
esophagogastric junction (7) 7
treatment outcome (7) 7
esophageal neoplasms - drug therapy (6) 6
esophagectomy (6) 6
gej cancer (6) 6
medicine & public health (6) 6
neoplasm staging (6) 6
barrett esophagus - pathology (5) 5
barretts-esophagus (5) 5
esophageal adenocarcinoma (5) 5
esophageal neoplasms - mortality (5) 5
esophagus (5) 5
gej adenocarcinoma (5) 5
pathology (5) 5
squamous-cell carcinoma (5) 5
adenocarcinoma - drug therapy (4) 4
adenocarcinoma - mortality (4) 4
adenocarcinoma - surgery (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
care and treatment (4) 4
cisplatin (4) 4
diagnosis (4) 4
esophageal neoplasms - metabolism (4) 4
esophageal neoplasms - surgery (4) 4
high-grade dysplasia (4) 4
neoadjuvant therapy (4) 4
review (4) 4
stomach neoplasms - drug therapy (4) 4
stomach neoplasms - pathology (4) 4
adenocarcinoma - therapy (3) 3
adjuvant treatment (3) 3
analysis (3) 3
biochemistry & molecular biology (3) 3
classification (3) 3
development and progression (3) 3
dysplasia (3) 3
esophageal (3) 3
esophageal neoplasms - therapy (3) 3
fluorouracil (3) 3
gastric (3) 3
gastric-cancer (3) 3
gastroenterology and hepatology (3) 3
immunohistochemistry (3) 3
immunotherapy (3) 3
intestinal metaplasia (3) 3
low-grade dysplasia (3) 3
metaplasia (3) 3
open-label (3) 3
ramucirumab (3) 3
review article (3) 3
ssbe (3) 3
stomach neoplasms - metabolism (3) 3
supportive care (3) 3
survival (3) 3
survival analysis (3) 3
survival rate (3) 3
therapy (3) 3
trial (3) 3
tumors (3) 3
abridged index medicus (2) 2
adenocarcinoma - metabolism (2) 2
advanced esophagogastric cancer (2) 2
advanced gastric-cancer (2) 2
alcian blue (2) 2
antineoplastic agents, immunological - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - pharmacology (2) 2
barrett’s esophagus (2) 2
biology (2) 2
biomarkers, tumor - analysis (2) 2
biopsy (2) 2
cancer research (2) 2
cardiac & cardiovascular systems (2) 2
chemoradiotherapy (2) 2
cisplatin - administration & dosage (2) 2
confidence intervals (2) 2
disease-free survival (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLOS ONE, ISSN 1932-6203, 04/2019, Volume 14, Issue 4, p. e0215089
Aim Barrett's esophagus (BE) is a predisposing factor of esophageal adenocarcinoma/gastroesophageal junction adenocarcinoma (ECA/GEJ Aca). BE patients are... 
DIAGNOSIS | ENDOSCOPY | LOW-GRADE DYSPLASIA | LIVER-INTESTINE-CADHERIN | INHIBITION | MANAGEMENT | MULTIDISCIPLINARY SCIENCES | SUBCELLULAR-LOCALIZATION | SURVEILLANCE | BARRETTS-ESOPHAGUS | TUMOR-SUPPRESSIVE MASPIN | Barrett Esophagus - metabolism | Adenocarcinoma - pathology | Metaplasia - metabolism | Serpins - metabolism | Humans | Esophagogastric Junction - metabolism | Esophagogastric Junction - pathology | Esophagus - metabolism | Precancerous Conditions - metabolism | Case-Control Studies | Disease Progression | Esophageal Neoplasms - pathology | Metaplasia - pathology | Esophagus - pathology | Adenocarcinoma - metabolism | Barrett Esophagus - pathology | Esophageal Neoplasms - metabolism | Biomarkers, Tumor - metabolism | Precancerous Conditions - pathology | Patient outcomes | Development and progression | Genetic aspects | Research | Gene expression | Esophageal cancer | Risk factors | Adenocarcinoma | Ethylenediaminetetraacetic acid | Dysplasia | Analysis | Diagnosis | Endoscopy | Tumor proteins | Immunohistochemistry | p53 Protein | Lung cancer | Staining | Oncology | Biology | Malignancy | Proteins | Histopathology | Endoscopes | Intestine | Mastectomy | Lesions | Localization | Distribution patterns | Gastroesophageal reflux | Statistical analysis | Breast cancer | Medical screening | Patients | Esophagus | Medicine | Pathology | Metaplasia | Surveillance | Biopsy | Medical prognosis | Epigenetics | Tumor suppressor genes | Diagnostic systems | Tumors
Journal Article
The Oncologist, ISSN 1083-7159, 01/2019, Volume 24, Issue 1, pp. 103 - 109
On September 22, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval for pembrolizumab (Keytruda, Merck & Co., Inc., Whitehouse... 
Accelerated approval | GEJ adenocarcinoma | PD‐L1 | PD-L1 | OXALIPLATIN | FLUOROURACIL | CANCER | CHEMOTHERAPY | TRIAL | SUPPORTIVE CARE | CISPLATIN | ONCOLOGY | RANDOMIZED PHASE-III | IRINOTECAN | PLUS | FDA | Regulatory Issues
Journal Article
The Oncologist, ISSN 1083-7159, 04/2019, Volume 24, Issue 4, pp. 475 - 482
Background The randomized phase III RAINBOW trial established paclitaxel (pac) plus ramucirumab (ram) as a global standard for second‐line (2L) therapy in... 
Second line | Ramucirumab | GEJ adenocarcinoma | Gastric cancer | FOLFIRI | MULTICENTER PHASE-II | JUNCTION CANCER | OPEN-LABEL | CHEMOTHERAPY | CAPECITABINE | HETEROGENEITY | CISPLATIN | ONCOLOGY | ADVANCED GASTRIC-CANCER | DOUBLE-BLIND | 1ST-LINE THERAPY | Index Medicus | Gastrointestinal Cancer
Journal Article
Journal Article
Journal Article
by Muro, K and Jen, MH and Cheng, R
CANCER MANAGEMENT AND RESEARCH, ISSN 1179-1322, 2019, Volume 11, pp. 2261 - 2267
Purpose: Second-line treatment with ramucirumab-paclitaxel has demonstrated statistically significant and clinically meaningful survival outcomes compared to... 
peritoneal metastases | gastric cancer | ONCOLOGY | safety | MALIGNANT ASCITES | GEJ | CANCER | efficacy
Journal Article
Journal of Clinical and Diagnostic Research, ISSN 2249-782X, 03/2015, Volume 9, Issue 3, pp. EC06 - EC10
Gastric cancer is one of the leading causes of cancer mortality in the world/India with majority being diagnosed at an advanced stage. Various chemotherapeutic... 
Gastric/GEJ adenocarcinoma | Immunohistochemistry (IHC) | HER2/neu | Pathology Section | Gastric | GEJ adenocarcinoma | HER2 | neu
Journal Article
Radiation Oncology, ISSN 1748-717X, 02/2013, Volume 8, Issue 1, pp. 33 - 33
Purpose: Multimodality therapy leads to improved outcomes for adenocarcinoma of the distal esophagus and gastroesophageal junction (GEJ) over surgery alone. At... 
IMRT | Gastro-esophageal junction | Adjuvant | GEJ | SIB | Simultaneous integrated boost | Gastro-oesophageal junction | SURGERY | METAANALYSIS | CANCER | ESOPHAGECTOMY | TRIAL | THERAPY | ONCOLOGY | NEOADJUVANT CHEMORADIOTHERAPY | CARCINOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Organs at Risk - radiation effects | Adenocarcinoma - pathology | Prognosis | Follow-Up Studies | Humans | Middle Aged | Male | Epirubicin - administration & dosage | Neoplasm Recurrence, Local - mortality | Chemoradiotherapy | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Neoplasm Recurrence, Local - pathology | Fluorouracil - administration & dosage | Esophageal Neoplasms - mortality | Female | Retrospective Studies | Chemotherapy, Adjuvant | Esophageal Neoplasms - therapy | Radiotherapy, Adjuvant | Radiotherapy Planning, Computer-Assisted | Neoplasm Recurrence, Local - therapy | Esophagogastric Junction - pathology | Survival Rate | Adenocarcinoma - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Radiotherapy, Conformal | Aged | Neoplasm Staging | Adenocarcinoma - mortality | Radiotherapy, Intensity-Modulated | Adenocarcinoma | Medical research | Care and treatment | Chemotherapy | Adjuvant treatment | Medicine, Experimental | Radiotherapy | Esophageal cancer | Cancer | Ethics | Survival analysis | Health sciences | Ostomy | Surgery | Oncology | Radiation therapy | Cancer therapies | Abdomen | Index Medicus | Reviews | Toxicity
Journal Article
Journal Article
Journal Article
Epigenetics, ISSN 1559-2294, 05/2015, Volume 10, Issue 5, pp. 431 - 445
Esophageal cancers are highly aggressive tumors with poor prognosis despite some recent advances in surgical and radiochemotherapy treatment options. This... 
azacytidine/gene pathway regulation | esophageal cancer | epigenetics/HDAC inhibitor | Azacytidine/gene pathway regulation | Epigenetics/HDAC inhibitor | Esophageal cancer | ESCC, esophageal squamous cell carcinoma | HDACi, HDAC inhibitor | H3K4me3, histone H3 trimethylation at lysine 4 | IN-VITRO | HDAC, histone deacetylases | SAHA, suberoylanilide hydroxamic acid | 5mC, 5-methylcytidine | MOUSE MODEL | GENETICS & HEREDITY | GENE-EXPRESSION | Hes-2, Hairy and enhancer of split 2 | HISTONE DEACETYLASE INHIBITOR | SUBEROYLANILIDE HYDROXAMIC ACID | INDUCED APOPTOSIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | FAIM, Fas apoptotic inhibitory molecule | DNMT, DNA (cytosine-5)-methyltransferase | VALPROIC ACID | EAC, esophageal adenocarcinoma | DAC, Decitabine | H3K9Ac, histone 3 lysine 9 acetylation | AZA, Azacytidine | TSA, Trichostatin A | GEJ, gastro-esophageal junction | DNA METHYLTRANSFERASE | NOTCH SIGNALING PATHWAY | H3Ac, histone H3 acetylation | TRANSFORMED-CELLS | Apoptosis - drug effects | Carcinoma, Squamous Cell - metabolism | Humans | Decitabine | Depsipeptides - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | DNA (Cytosine-5-)-Methyltransferases - metabolism | Adenocarcinoma - metabolism | Esophageal Neoplasms - metabolism | Benzamides - pharmacology | Hydroxamic Acids - pharmacology | Esophageal Squamous Cell Carcinoma | DNA Damage - drug effects | Cell Survival - drug effects | DNA (Cytosine-5-)-Methyltransferase 1 | Azacitidine - analogs & derivatives | Transcriptome - drug effects | Adenocarcinoma - drug therapy | Azacitidine - pharmacology | Cell Movement - drug effects | Acetylation - drug effects | Carcinoma, Squamous Cell - drug therapy | Cell Cycle Checkpoints - drug effects | Vorinostat | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Pyridines - pharmacology | Histones - metabolism | Esophageal Neoplasms - drug therapy
Journal Article